Delhi High Court has decided to put the government’s ban on over 300 odd drugs on hold till the court’s hearing on March 29.
Seeking intervention from High Court, many pharma companies like Glenmark, Pfizer, Abbott India, Macleods, Reckitt Benckiser, Piramal Enterprises, Alembic Pharma and Procter and Gamble (P&G) requested Delhi High court to review the fixed combination drugs report that has got them banned.
They had asked the manufacturing companies to stop sale and distribution of these fixed drug combinations, stating that they had “no therapeutic justification” and “likely to involve risk to human beings”.
The ban on these drugs were decided after the government reviewed a report constituted by a panel under Professor Chandrakant Kokate, which was reviewing fixed combination drugs.
The government has in turn presented an counter argument that there is not much data available on drug-drug interaction and side-effects in fixed dose combination drugs and thus sale of these drugs should be stopped.
To make their case stronger they added that most developed countries do not allow these drugs in their market and even the doctors welcomed the ban with open arms.